Effect of antiretroviral therapy on apoptosis markers and morphology in peripheral lymph nodes of HIV-infected individuals

Infection

Volumn 36, Issue 2, 2008, Pages 120-129

  Ehrhard, S ^a   Wernli, M ^a   Kaufmann, G ^b   Pantaleo, G ^c   Rizzardi, G P ^d   Gudat, F ^e   Erb, P ^a   Battegay, M ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CASPASE 3; FAS ANTIGEN; INTERLEUKIN 7 RECEPTOR ALPHA; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; INGUINAL LYMPH NODE; LYMPH NODE HYPERPLASIA; MALE; MEDICAL ETHICS; MORPHOLOGY; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; GERMINAL CENTER; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 42249094734     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7368-9     Document Type: Article

References (44)

1. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-1686.
2. Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, Bart PA, Miller V, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JM, Lazzarin A, Pantaleo G: Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest 2000; 105: 777-782.
3. Battegay M, Nuesch R, Hirschel B, Kaufmann GR: Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6: 280-287.
4. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-362.
5. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-358.
6. Schacker T, Little S, Connick E, Gebhard K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong JK, Schooley RT, Richman D, Corey L, Haase AT: Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis 2001; 183: 555-562.
7. Pantaleo G, Fauci AS: New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995; 13: 487-512.
8. Chadburn A, Metroka C, Mouradian J: Progressive lymph node histology and its prognostic value in patients with acquired immunodeficiency syndrome and AIDS-related complex. Hum Pathol 1989; 20: 579-587.
9. Laman J, Claassen E, Van Rooijen N: Immune complexes on follicular dendritic cells as a target for cytolytic cells in HIV. AIDS 1989; 30: 543-548.
10. Baroni C, Vitolo D, Uccini S: Immunohistopathogenesis of persistent lymphadenopathy in HIV-positive patients. Ric Clin Lab 1990; 20: 1-10.
11. Zhang ZQ, Schuler T, Cavert W, Notermans DW, Gebhard K, Henry K, Havlir DV, Gunthard HF, Wong JK, Little S, Feinberg MB, Polis MA, Schrager LK, Schacker TW, Richman DD, Corey L, Danner SA, Haase AT: Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci USA 1999; 96: 5169-5172.
12. Badley AD, Pilon AA, Landay A, Lynch DH: Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000; 96: 2951-2964.
13. McCune JM: The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001; 410: 974-979.
14. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE: CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?. Nat Med 2002; 8: 319-323.
15. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200: 749-759.
16. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M: Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200: 761-770.
17. Gougeon ML, Montagnier L: Apoptosis in AIDS. Science 1993; 260: 1269-1270.
18. Ameisen JC, Estaquier J, Idziorek T, De Bels F: Programmed cell death and AIDS pathogenesis: significance and potential mechanisms. Curr Top Microbiol Immunol 1995; 200: 195-211.
19. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995; 1: 129-134.
20. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W, Gebhard K, Staskus K, Zhang ZQ, Dailey PJ, Balfour HH Jr., Erice A, Perelson AS: Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274: 985-989.
21. Ost A, Baroni CD, Biberfeld P, Diebold J, Moragas A, Noel H, Pallesen G, Racz P, Schipper M, Tenner-Racz K, et al. Lymphadenopathy in HIV infection: histological classification and staging. Acta Pathol Microbiol Scand 1989; 97: 7-15.
22. Bachmann F, Buechner SA, Wernli M, Strebel S, Erb P: Ultraviolet light downregulates CD95 ligand and trail receptor expression facilitating actinic keratosis and squamous cell carcinoma formation. J Invest Dermatol 2001; 117: 59-66.
23. Orenstein JM, Feinberg M, Yoder C, Schrager L, Mican JM, Schwartzentruber DJ, Davey RT Jr, Walker RE, Falloon J, Kovacs JA, Miller KD, Fox C, Metcalf JA, Masur H, Polis MA: Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. Aids 1999; 13: 2219-2229.
24. Kuster H, Opravil M, Ott P, Schlaepfer E, Fischer M, Gunthard HF, Luthy R, Weber R, Cone RW: Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. Am J Pathol 2000; 156: 1973-1986.
25. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Gunthard HF: Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis 2004; 190: 1979-1988.
26. Voltersvik P, Dyrhol-Riise AM, Bostad L, Rosok BI, Olofsson J, Asjo B: Changes in tonsillar tissue in early HIV-1 infection and during 3 years of antiretroviral therapy. Apmis 2000; 108: 539-550.
27. Alos L, Navarrete P, Morente V, Garcia F, Garrido M, Plana M, Mozos A, Lopez A, Gil C, Pumarola T, Caballero M, Blanch JL, Fumero E, Miro JM, Gallart T, Gatell JM, Campo E: Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Mod Pathol 2005; 18: 127-136.
28. Blackbourn DJ, Mackewicz CE, Barker E, Hunt TK, Herndier B, Haase AT, Levy JA: Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. Proc Natl Acad Sci USA 1996; 93: 13125-13130.
29. Rizzardi GP, Tambussi G, Bart PA, Chapuis AG, Lazzarin A, Pantaleo G: Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. Aids 2000; 14: 2257-2263.
30. Dyrhol-Riise AM, Voltersvik P, Rosok BI, Olofsson J, Asjo B: Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection. AIDS Res Hum Retrovir 2000; 16: 191-201.
31. Petit F, Arnoult D, Lelievre JD, MoutouhdeParseval L, Hance AJ, Schneider P, Corbeil J, Ameisen JC, Estaquier J: Productive HIV-1 infection of primary CD4+T cells induces mitochondrial membrane permeabilization leading to a caspase-independent cell death. J Biol Chem 2002; 277: 1477-1487.
32. Boudet F, Lecoeur H, Gougeon ML: Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. J Immunol 1996; 156: 2282-2293.
33. Regamey N, Harr T, Battegay M, Erb P: Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2. AIDS Res Hum Retrovir 1999; 15: 803-810.
34. Airo P, Torti C, Uccelli MC, Malacarne F, Palvarini L, Carosi G, Castelli F: Naive CD4+ T lymphocytes express high levels of Bcl-2 after highly active antiretroviral therapy for HIV infection. AIDS Res Hum Retrovir 2000; 16: 1805-1807.
35. Balestrieri E, Grelli S, Matteucci C, Minutolo A, d'Ettorre G, Di Sora F, Montella F, Vullo V, Vella S, Favalli C, Macchi B, Mastino A: Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. J Med Virol 2007; 79: 111-117.
36. Koesters S, Alimonti J, Wachihi C, Matu L, Anzala O, Kimani L, Embree J, Plummer F, KR F: IL-7Ralpha expression on CD4+ T lymphocytes decrease with HIV disease progression and inversely correlates with immune activation. Eur J Immunol 2006; 36: 336-344.
37. Rethi B, Fluur C, Atlas A, Krzyzowska M, Mowafi F, Grutzmeier S, De Milito A, Bellocco R, Falk KI, Rajnavolgyi E, Chiodi F: Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. Aids 2005; 19: 2077-2086.
38. Miura Y, Koyanagi Y: Death ligand-mediated apoptosis in HIV infection. Rev Med Virol 2005; 15: 169-178.
39. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Tijoe IM, Smith CA, Herzenberg LA: Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection: TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J Exp Med 1997; 186: 1365-1372.
40. Jeremias I, Herr I, Boehler T, Debatin KM: TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998; 28: 143-152.
41. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, Lazzarin A, Pantaleo G: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109: 681-688.
42. Cohen OJ, Fauci AS: Benchmarks for antiretroviral therapy. J Clin Invest 2000; 105: 709-710.
43. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P, Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M: Lack of Mucosal Immune Reconstitution during Prolonged Treatment of Acute and Early HIV-1 Infection. PLoS Med 2006; 3: e484.
44. Veazey RS, Lackner AA: Impact of antiretroviral therapy on intestinal lymphoid tissues in HIV infection. PLoS Med 2006; 3: e515.